



Institutional Biosafety Committee Minutes

Date: Wednesday, March 18, 2026

Time: 9:30 AM

Location: Zoom Meeting

MEMBERS IN ATTENDANCE

Busch, Robert H
Carroll, Ann M.
Finkernagel, Scott W.
Geri, Jacob
Kalisvaart, Anna
Kaminsky, Stephen M.
Lieggi, Christine
McGuinn, Catherine
Ndhlovu, Lishomwa (Lish)
Otero, Miguel
Repik, Gabrielle
Schnappinger, Dirk
Wagner, John A.

MEMBERS ABSENT

STAFF

Gonzalez Russi, Sabrina
Lejb, Katarzyna

Meeting Minutes for Approval:

- February 18, 2026

No issues were raised and the committee approved the minutes from February 18, 2026.

Safety Officer Report

New Business

Conflicts of Interest Disclosure:

No member of the IBC may participate in the review of any project in which the IBC member is an investigator, has a financial conflict of interest, or has any other interest which has an adverse impact on the IBC member's ability to exercise independent judgment. Under such circumstances, the IBC member shall not be present during IBC deliberations, except to provide information requested by the IBC. Each member of the IBC shall respect and preserve the confidentiality of information he/she receives as a member of the IBC, and shall use, discuss, and/or disclose such information only for purposes related to deliberations or other assigned business of the IBC.

- *Dr. Otero reported a Conflict of Interest with Dr. Rodeo, Dr. Moore, Dr. Chen, and his own registration. Dr. Otero will abstain from voting on these registrations.*
- *Dr. McGuinn reported a Conflict of Interest with her own registration. Dr. McGuinn will abstain from voting on this registration.*

Protocols on Agenda

The Institutional Biosafety Committee (IBC) and Biosafety staff perform pre-reviews on all protocol submissions, including consideration of: agent characteristics (e.g., virulence, pathogenicity, environmental stability, replication competence), the types of manipulations planned, the sources of nucleic sequences (species), the nature of the nucleic acid sequences (e.g., structural, enzyme, oncogene, toxin, gene regulator), the hosts and vectors to be used, whether an attempt will be made to obtain expression of a transgene, and if so, the function of the protein in the proposed system.

IBC review includes: (i) independent assessment and setting of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in recombinant or synthetic nucleic acid molecule research; (iii) for recombinant or synthetic nucleic acid molecule research involving human research participants assessment focused on biosafety issues (e.g., administration, shedding) (iv) set containment levels in concert with the WCM IACUC.

Prior to reviewing a registration at the IBC meeting, the Principal Investigators laboratory is inspected to confirm that facilities and biocontainment equipment (e.g., certified Class II biological safety cabinets) are available and appropriate. We also determine if all laboratory personnel are appropriately trained to adhere to institutional and federal regulations to ensure the safe and compliant conduct of research.

All protocol submissions are made available to IBC members before the meeting. During the meeting, reviewers' and members' questions are presented, discussed, and sufficiently addressed. Protocols are voted on and acted upon by the IBC, i.e., applications are either approved, rejected or returned to the applicant to request clarifying information. Protocols deemed to require changes are returned to the PI for revision before subsequent review by the IBC. Principal Investigators are then provided the results of the IBC review and official approval.

Following initial approval, IBC registration remains valid for a period of two years. During this two-year period, laboratory inspections and review of training records of lab staff are conducted annually in accordance with Weill Cornell policies.

Human Subjects Research/Human Gene Transfer: Initial

HS Record Number: 25-09029358

HS PI Name: McGuinn, Catherine

Record Title:

A Phase 2b, Single-Arm, Open-Label, Multicenter Study of the Safety of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

RS Record Number: 25-0121

Notes: The assigned IBC member reviewed the protocol. The reviewer noted that the IBC application states that replication competent AAV testing is not done. No issues were raised. The reviewer recommended approval at BSL-2 with standard contact precautions.

Decision: Approved

HS Record Number: 25-11029545

HS PI Name: Grinspan, Zachary

Record Title:

Single Patient Evaluation with Intracerebral Ventricular scAAV9-CSA Gene therapy in a pediatric subject with Cockayne Syndrome due to mutations in the ERCC8/CSA gene

RS Record Number: 25-0112

Notes: The assigned IBC member reviewed the protocol. The reviewer noted several concerns related to patent risk and study product preparation. The IBC agreed to notify the IRB and the PI regarding these matters. No other issues were raised. The reviewer recommended approval at BSL-2 with standard contact precautions.

Decision: Approved

HS Record Number: 26-01029737

HS PI Name: Mejia Saldarriaga, Mateo

Record Title:

CA088-1007: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucl (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUI NTESSENTIAL-2)

RS Record Number: 26-0002

Notes: The assigned IBC member reviewed the protocol. No issues were raised. The reviewer recommended approval at BSL-2 with standard droplet/contact precautions.

Decision: Approved

Laboratory Safety Registrations - 2-Year Renewals

Record Number: 19-0576

PI Name: Scott A. Rodeo

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommended approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism or Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated /packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, upregulated downregulated, or deleted	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		Adenovirus, serotype 5 (Ad5), replication deficient.	Replication Incompetent/ Deficient	293T Cell	Both	Animal	We will evaluate the application of Adenovirus, serotype 5 (Ad5) to express DNA binding and transcriptional factors (such as BMP2, Scleraxis (Sx), SR Y-box (Sox9), and Gli1), growth factors CTGF, VEGF and luciferase. To demonstrate the transfection efficiency of Ad5 vector we will also use a vector with mCherry reporter gene. The Ad5-Null, the same backbone with a non-translatable sequence in the expression cassette region will be a negative control.	Human ~ Murine	Cytokine ~ Gene Expression Regulators ~ Marker/Reporter	Create virions ~ Transfect cells / introduce into in vivomodel	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3 ~ Section III-D-4

Record Number: 19-0628

PI Name: Julie Magarian Blander

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted the additional work with human corona virus and SARS-CoV-2. The reviewer suggested requesting clarification on the pathogens listed as there were some discrepancies on the eForm, specifically introduction to *in vivo* models. The IBC also requested to implement more education for vaccine and risk knowledge, as well as a declination form with Workforce Health and Safety. No other issues were raised. The reviewer recommended approval at previously approved biosafety levels.

Decision: Approval pending

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		VSV-pseudotyped lentivirus	Replication Incompetent / Deficient ~ Self-Inactivating	293T	In Vitro	In vivo~ Human	Rab GTPases and SNAREs will be suppressed. Pattern recognition signaling molecules downstream of TLRs, NLRs, and RLRs will be expressed.	Virus	Other/ Transduction of primary cells- regulation of vesicular traffic within cells	Express/ Upregulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3
Escherichia Coli		(Migula) Castellani and Chalmers ATCC(R) 11775, NC TC 9001	Attenuated ~ Replication Competent	E. coli	Both	In vivo~ Bacterial	ovalbumin protein	Other/ G. gallus	Allergen	Direct inject into in vivomodel ~ Other/ E.Coli grown in Culture then added to cultured murine phagocytes	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-4

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
*Other	Murid herpesvirus 1 (MuHV-1) (Mouse cytomegalovirus)	Murid herpesvirus 1 (ATCC(R) VR-1399)	Replication Competent	Both	Conduct Multiplicity of infection (MOI) studies ~ Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Shigella [Flexneri]		Flexneri BS103	Attenuated ~ Replication Competent	In Vitro	Culturing	BSL-2	Not rDNA	
Salmonella [Typhimurium]		typhimurium	Replication Competent	In Vitro	Culturing	BSL-2	Not rDNA	
Listeria [Monocytogenes]		ATCC #19115	Replication Competent	Both	Culturing ~ Introduction into in vivomodel	BSL-2	Not rDNA	
Cytomegalovirus	Cytomegalovirus	hCMV (non-neurotropic)	Replication Competent	In Vitro	Conduct Multiplicity of infection (MOI) studies ~ Culturing ~ Isolation DNA/RNA	BSL-2	Not rDNA	
Yersenia [Pestis]		BEI NR4681 Kim 19 Derivative	Attenuated Replication Competent	~ In Vitro	Culturing	BSL-2	Not rDNA	
*Other	Stable Bone Marrow Derived Macrophage with recombinant retrovirus	J-2 recombinant retrovirus	Replication Competent	In Vitro	Culturing	BSL-2	Not rDNA	
Cowpox Virus [Poxviridae/Orthopox virus]		(ATCC(R) VR30™)	Replication Competent	Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Influenza Virus [Orthomyxoviridae Types A, B, C]		A/California/07/2009 (H1N1)pdm09, A/Perth/16/2009 (H3N2)), attenuated B/Brisbane/60/2008	Attenuated Replication Competent	~ Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Citrobacter [Rodentium]		DBS600	Replication Competent	In Vivo	Introduction into in vivomodel	ABSL-1 ~ BSL-1	Not rDNA	
*Other	Listeria innocua	Listeria innocua Seeliger- ATCC #33091	Attenuated Replication Competent	~ Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Bacillus [Anthraxis (Sterne, delta Sterne)]		Sterne 34F2 (LL NL A0517), NR-1400 which we will obtain through the NIH NIAID BEI Repository	Attenuated Replication Competent	~ Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Staphylococcus [Aureus]		ATCC #12600, Sar-Avr- mutant lacking these regulatory factors	Replication Competent	In Vitro	Culturing	BSL-2	Not rDNA	

Francisella [Tularensis]		BEI NR-13 Utah 112	Attenuated Replication Competent	~	In Vitro	Culturing	BSL-2	Not rDNA	
Influenza Virus [Orthomyxoviridae Types A, B, C]		A/PR/8/34, X-31	Attenuated Replication Competent	~	Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Influenza Virus [Orthomyxoviridae Types A, B, C (Vaccine Strain)]		Netherlands/262 9/2009(H1N1) pd m09	Replication Competent		Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Inactivated Coronavirus (RIPA lysate or PFA fixed cells)	HCoV-OC43, HCoV-NL63, HCoV-229E, MERS-CoV (Ithaca Collaborator)	Attenuated Replication Incompetent/Deficient	~	In Vitro	Isolation DNA/RNA ~ Other/We will run SDS-PAGE on Coronavirus inactivated RIPA lysates to study innate immune activation	BSL-2	Not rDNA	
*Other	Burkholderia cenocepacia	LMG 16656	Replication Competent		In Vitro	Conduct Multiplicity of infection (MOI) studies ~ Culturing	BSL-2	Not rDNA	
*Other	Inactivated SARS-CoV-2 RIPA lysates	SARS-CoV-2 (MSSM-collaborator)	Attenuated		In Vitro	Isolation DNA/RNA ~ Other/We will run SDS-PAGE on SARS-CoV-2 inactivated RIPA lysates to study innate immune activation	BSL-2	Not rDNA	
*Other	SARS-CoV-2	hCoV NL63, SARS-CoV-2: BQ.1	Replication Competent		Both	Conduct Multiplicity of infection (MOI) studies~ Introduction into in vivomodel	BSL-2	Not rDNA	

Record Number: 19-0633

PI Name: Mary E. Choi

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and requested that we return this protocol to the PI to review and correct the laboratory overview section. No other issues were raised. The reviewer recommended the renewal be tabled and re-reviewed after a more detailed description is provided.

Decision: Registration approval tabled

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/ vector will be propagated/ packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		pACCMVpLpA-Akt	Replication Incompetent/Deficient	293 cell	In Vitro	Human	Akt, MLKL, PARKIN, Mitofusin 1, Mitofusin 2	Human	Oncogenic Gene Sequences~ Other	Create virions~ Express/Upregulate gene of interest~ Transfect cell line	BSL-2	NIH Applicable	Section III-D-1~Section III-D-3
Lentivirus [Retroviridae/Lentiviridae]		Lenti-CAS9-Blast, Lenti-sgRNA-Puro, Lenti-dCAS9-Blast, Lenti-CAS9-2A-Blast, Lenti-sgRNA-Pure, Lenti-dCAS9	Replication Competent	293T	In Vitro	In vivo~ Bacterial	RIPK3, MLKL, PINK1, Parkin, Mitofusin 1, Mitofusin 2	Human~ Murine	Gene Expression Regulators	Create virions~ Express/Upregulate gene of interest~ Repress/Downregulate gene of interest~ Transfect cell line~ Transfect cells	BSL-2	NIH Applicable	Section III-D-1~Section III-D-3

Record Number: 19-0666

PI Name: Matthew Edward Cunningham

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with renewal. The reviewer requested to indicate both in vitro and in vivo, and oncogenes, for both microorganisms. Additionally, the reviewer requested to inquire about the status of “TBD” listed under the IACUC protocol for Retrovirus. No other issues were raised. With these administrative changes, the reviewer recommended approval at previously approved biosafety levels.

Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Retrovirus [Amphotropic]		pMXs-IRES-Bst, pMXs-IRES-Neo, pMXs-U6-puro	Replication Incompetent/ Deficient	HEK293, phoenix 293	Both	In vivo~ Human	Platelet derived growth factor (PDGF-BB), Tissue non-specific alkaline phosphatase (TNAP), progressive ankylosis (ANK) gene, ectonucleotide pyrophosphatase/p hosphodiesterase (ENPP), Tumor necrosis factor (TNF-alpha), IL-1-beta, BMP6, BMP9	Human ~ Murine ~ Other/Bovine	Cytokine ~ Gene Expression Regulators ~ Oncogenic Gene Sequences ~ Other/enzyme	Create virions ~ Express/Uregulate gene of interest ~ Other /to reprogram human and bovine cells to up/down regulate specific genes~ Transfect cell line ~ Transfect cells / introduce into in vivomodel	ABSL-2 ~BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3 ~ Section III-D-4
Adenovirus [Human, all types]		E1 deficient and partially E3 deficient	Replication Incompetent/ Deficient	HEK293	Both	In vivo~ Human	Tumor necrosis factor (TNF-alpha), TG F-beta family (BM P2, BMP7), betagalactosidase (beta-GAL)	Bacteria ~ Human	Cytokine ~ Marker/Reporter ~ Oncogenic Gene Sequences ~ Other/enzyme , cytokine	Create virions ~ Express/Uregulate gene of interest ~ Other/to reprogram bovine or human nucleus pulposus cells~ Transfect cell line ~ Transfect cells / introduce into in vivomodel	ABSL-2 ~BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-4

Record Number: 23-0154

PI Name: Lisa Giulino Roth

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted the removal of in vivo sources of biologic material. Although this was removed, the biohazard table mentions NHP cell lines. The reviewer requested clarification on this. No other issues were raised. With these administrative changes, the reviewer recommended approval at previously approved biosafety levels.

Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)
Lentivirus [Retroviridae/Lentiviridae]		pLKO.1, pTRIPZ, pGIPZ	Replication Incompetent/Deficient	293T, 293TN	Both	In vivo~ Human	shRNA to NFkB, gene family, vFLIP, LM P-1, PI3K/Akt/mTOR, expression of vFLIP, and KSHV, EBV genes, NFkB family genes, TRIC library	Human ~ Murine ~ Virus	Gene Expression ~ Regulators ~ Oncogenic Gene Sequences	Create virions ~ Direct inject into in vivomodel ~ Express/Up regulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line ~ Transfect cells / introduce into in vivomodel	ABSL-2 ~ BSL-2+
Bacterial Expression Vector		pGEX, pET, pT7 -Flag-based vectors, BAC16 (bacterial artificial chromosome), EBV from Akata cell line	Replication Competent ~ Replication Incompetent/Deficient	E.Coli (DH5alpha), iSLK	Both	Bacterial ~ Human	KSHV vFLIP, EBV LMPI, TRAF2, IKKgamm, KSHV	Human ~ Virus	Antibiotic Resistance ~ Gene Expression Regulators ~ Oncogenic Gene Sequences	Express/ Upregulate gene of interest ~ Transfect cells / introduce into in vivomodel	ABSL-2 ~ BSL-2+
Human Immunodeficiency Virus (HIV) [Retroviridae/Lentiviridae Types 1 and 2]		defective HIV system, JLat 10.6, which is a Jurkat T-lymphocyte cell line from the HIV AIDS reagents program containing the retroviral construct HIV-R7/ E-/GFP	Replication Incompetent/Deficient	Jurkat T-lymphocyte cell line	In Vitro	Human	full length HIV-1 genome with a non-functional Env due to a frameshift, and GFP in place of the Nef gene.	Virus	Marker/ Reporter	Create virions ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line	BSL-2

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Kaposi sarcoma associated herpes virus [Herpesviridae/Gammapherpesvirinae/HHV8]	Bacterial Expression Vector	BC1, BC3, BCP1, BCBL-1, JSC-1 cell lines	Replication Competent	Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	
Epstein-Barr virus (EBV) [Herpesviridae/Gamma-herpesviridae]		IBL-1, IBL-4, LC L9001, Bc1, BC3 cell lines	Replication Competent	Both	Culturing ~ Introduction into in vivomodel	ABSL-2 ~ BSL-2	Not rDNA	

Record Number: 24-0037

PI Name: Juan M. Pascual

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommended approval at previously approved biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
------------------------------------	--------------------------	---------------------------------------	----------------------------------	---	----------------------	---------------------------	--	---------------------------------------	--	--------------------------------------	-----------------------------	----------------------	---------------------------

Adeno-Associated Virus (AAV)		AAV serotypes 1 and 2 AAV Serotypes 5,8,9 RetroAAV2.Cre.GFP, RetroAAV2.GFP AAV5-EF1a-DIO-eNpHR3.0 -EYFP (halorhodopsin) AAV5-EF1a-DIO-ChR2 (channelrhodopsin)	Replication Incompetent/Deficient	293 cells	Both	Animal	GCaMP, GFP/RF P, Cre, D READD, channelrhodopsin, halorhodopsin, Na b2	Bacteria ~ Bacteriophage ~ Jellyfish ~ Virus	Gene Expression Regulators ~ Marker/Reporter ~ Other/Pathology	Direct inject into in vivomodel ~ Express/Upreregulate gene of interest ~ Repress/Dowregulate gene of interest	ABSL-1 ~ BSL-2	NIH Applicable	Section II I-D-4
------------------------------	--	---	-----------------------------------	-----------	------	--------	---	--	--	--	----------------	----------------	------------------

Acknowledgement of Laboratory Safety Registrations: No IBC-Applicable Work Conducted

Record Number	PI Name	Laboratory Safety Registration Submission Type
19-0675	Kangpu Xu	Lab Registration - Renewal
19-0686	Celeste Abjornson	Lab Registration - Renewal
23-0145	Oleh M. Akchurin	Lab Registration - Renewal
24-0029	Laura Moore	Lab Registration - Renewal
26-0008	Tony Chen	Lab Registration - Initial

Laboratory Safety Registrations: Exempt

Record Number	PI Name	Laboratory Safety Registration Submission Type
19-0670	Miguel Otero	Lab Registration - Renewal

Request for Extension of Expiration Date to April 15, 2026

Record Number	PI Name
24-0035	Lan Zhou

The meeting adjourned at 10:53 AM.